{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:22:09Z","timestamp":1724890929111},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpet.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T21:26:53Z","timestamp":1719696413000},"page":"447-462","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in\u00a0Hodgkin\u2019s and Non-Hodgkin Lymphomas"],"prefix":"10.1016","volume":"19","author":[{"given":"Nadia","family":"Withofs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hustinx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpet.2024.05.001_bib2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas. Version 1.2024 \u2014 January 18, 2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"7","key":"10.1016\/j.cpet.2024.05.001_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.cpet.2024.05.001_bib4","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.cpet.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international Conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.cpet.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2967\/jnumed.122.264106","article-title":"Application of the Lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the PRoLoG consensus initiative (Part 1-clinical)","volume":"64","author":"Ricard","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2967\/jnumed.122.264124","article-title":"Application of the Lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the PRoLoG consensus initiative (Part 2-Technical)","volume":"64","author":"Ricard","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(23)00030-3","article-title":"European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours","volume":"10","author":"Nanni","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpet.2024.05.001_bib10","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hodgkin Lymphoma. Version 1.2024-October 12, 2023 \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"21","key":"10.1016\/j.cpet.2024.05.001_bib11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. International prognostic factors Project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.cpet.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"38","author":"Fuchs","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"Calgb 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.cpet.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted Intergroup EORTC\/LYSA\/FIL H10 trial for Localized hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.cpet.2024.05.001_bib19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.cpet.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.cpet.2024.05.001_bib23","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpet.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2016.03.005","article-title":"PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis","volume":"101","author":"Sickinger","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"Guideline for the first-line management of classical hodgkin lymphoma - a British Society for Haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.001_bib27","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"Gillessen","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.cpet.2024.05.001_bib29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cpet.2024.05.001_bib30","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography-driven strategy in advanced hodgkin lymphoma: Prolonged follow-up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10114","key":"10.1016\/j.cpet.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.cpet.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials","volume":"9","author":"Andre","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.2838","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study","volume":"39","author":"Hutchings","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.001_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.cpet.2024.05.001_bib38","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.cpet.2024.05.001_bib39","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-023-06431-w","article-title":"Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group","volume":"51","author":"Ferdinandus","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib42","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cpet.2024.05.001_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19273","article-title":"The management of newly diagnosed large B-cell lymphoma: a British Society for Haematology Guideline","author":"Fox","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.001_bib45","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA","volume":"5","author":"Kostakoglu","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"issue":"10216","key":"10.1016\/j.cpet.2024.05.001_bib48","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.cpet.2024.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/hon.5_2879","article-title":"Early positron emission tomography response-adapted treatment in Localized diffuse large B-cell lymphoma (Aaipi=0) : results of the phase 3 Lysa Lnh 09-1b trial","volume":"39","author":"Bologna","year":"2021","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1016\/j.cpet.2024.05.001_bib50","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National clinical trials Network study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.cpet.2024.05.001_bib51","first-page":"1549","volume":"130","author":"Pfreundschuh","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.001_bib52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.121.262205","article-title":"18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: the HOVON-84 study","volume":"63","author":"Burggraaff","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.001_bib53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.122.264740","article-title":"Prognostic value of 18F-FDG PET\/CT in diffuse large B-cell lymphoma treated with a risk-adapted Immunochemotherapy regimen","volume":"64","author":"Michaud","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.001_bib54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(dagger)","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.001_bib55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of\u00a0metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.001_bib56","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2967\/jnumed.123.267022","article-title":"Is 18F-FDG metabolic tumor volume in lymphoma really happening?","volume":"65","author":"Barrington","year":"2024","journal-title":"J\u00a0Nucl Med"},{"issue":"21","key":"10.1016\/j.cpet.2024.05.001_bib57","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new Dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.cpet.2024.05.001_bib58","first-page":"3055","article-title":"Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma","volume":"141","author":"Eertink","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.001_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2967\/jnumed.119.238923","article-title":"Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium","volume":"62","author":"Barrington","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"S1","key":"10.1016\/j.cpet.2024.05.001_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.3154","article-title":"The evolving therapy of DLBCL: bispecific antibodies","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.120.244145","article-title":"Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: comparison of the Deauville 5-point scale and the DeltaSUV(max) method","volume":"62","author":"Rekowski","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib62","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.clml.2022.11.009","article-title":"Interim FDG18-PET SUV(max) variation adds prognostic value to Deauville 5-point scale in the identification of patients with ultra-high-risk diffuse large B cell lymphoma","volume":"23","author":"Duarte","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.001_bib63","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2021.1948028","article-title":"End-of-treatment 18F-FDG PET\/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score","volume":"62","author":"Allioux","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.001_bib64","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","article-title":"Validation of the DeltaSUV(max) for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical trial","volume":"64","author":"Itti","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.001_bib65","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-021-05498-7","article-title":"Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements","volume":"49","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib66","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib67","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma","volume":"56","author":"Danylesko","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.001_bib68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","article-title":"[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies","volume":"49","author":"Cohen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.001_bib69","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"issue":"18","key":"10.1016\/j.cpet.2024.05.001_bib70","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: Updated analyses of the German hodgkin study group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.cpet.2024.05.001_bib71","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study","volume":"39","author":"Oeffinger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib72","doi-asserted-by":"crossref","first-page":"e2351062","DOI":"10.1001\/jamanetworkopen.2023.51062","article-title":"Late cardiac toxic effects associated with treatment protocols for hodgkin lymphoma in children","volume":"7","author":"Lo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.001_bib73","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood.2020007225","article-title":"Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"137","author":"Giulino-Roth","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.001_bib74","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.001_bib76","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.cpet.2024.05.001_bib77","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.21.00068","article-title":"Gonadal function recovery in patients with advanced hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011)","volume":"39","author":"Demeestere","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"van Heek","year":"2022","journal-title":"BMC Cancer"},{"issue":"7996","key":"10.1016\/j.cpet.2024.05.001_bib79","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by\u00a0noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.001_bib80","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/bloodadvances.2023010798","article-title":"Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort","volume":"8","author":"Ghesquieres","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.001_bib81","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.semnuclmed.2022.11.003","article-title":"Role of artificial intelligence in PET\/CT imaging for management of lymphoma","volume":"53","author":"Veziroglu","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.001_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cpet.2021.09.006","article-title":"Artificial intelligence in lymphoma PET imaging: a scoping review (current trends and future directions)","volume":"17","author":"Hasani","year":"2022","journal-title":"Pet Clin"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T22:04:28Z","timestamp":1724882668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1556859824000476"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.001","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in\u00a0Hodgkin\u2019s and Non-Hodgkin Lymphomas","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}